UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported):~~1934

~~January~~Date 3of Report (Date of earliest event reported): February 20, 2019

~~IMMUNE~~Immune ~~DESIGN~~Design ~~CORP~~Corp.

(Exact name of registrant as specified in its charter)

Delaware	~~001-36561~~	26001-~~2007174~~36561	26-2007174
(state or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or other jurisdiction of incorporation)		(Commission File Number)	(I.R.S. Employer Identification No.)
1616 Eastlake Ave. E., Suite 310Seattle, Washington			98102
(Address of principal executive offices)			(Zip Code)

1616 Eastlake Ave. E., Suite 310Seattle, Washington		98102
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (206) 682-0645

Registrant's telephone number, including area code: (206) 682-0645

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o ☒ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Emerging~~Indicate by check mark whether the registrant is an emerging growth company xas defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

IfEmerging ~~an emerging~~ growth company, ☒ indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

~~Item~~If ~~5.02.~~an ~~Departure~~emerging ofgrowth ~~Directors~~company, orindicate ~~Certain~~by ~~Officers;~~check ~~Election~~mark ofif ~~Directors;~~the ~~Appointment~~registrant ofhas ~~Certain~~elected ~~Officers;~~not ~~Compensation~~to ~~Arrangements~~use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of ~~Certain~~the ~~Officers~~Exchange Act. ☒

OnItem ~~January 3, 2019, the Compensation Committee (the “Committee”) of the Board of Directors of Immune Design Corp~~1.01 ~~(the~~Entry ~~“Company”)~~into ~~approved~~a ~~2018~~Material ~~cash~~Definitive ~~bonuses, 2019 annual base salaries and equity awards for the Company’s named executive officers (each, an “Executive”), as set forth below~~Agreement. ~~Bonus targets for the Executives were unchanged.~~

~~2018~~Agreement ~~Cash Bonuses~~ and ~~2019~~Plan ~~Annual~~of ~~Base~~Merger ~~Salaries~~

~~The~~On ~~Committee~~February 20, ~~approved~~2019, Immune Design Corp., a Delaware corporation (the ~~following~~“Company” ~~2018~~or ~~cash~~“Immune Design”), ~~bonuses~~entered into an Agreement and ~~2019~~Plan ~~annual~~of ~~base~~Merger ~~salaries~~(the “Merger Agreement”) with Merck Sharp & Dohme Corp., ~~which~~a ~~salaries~~New ~~are~~Jersey ~~effective~~corporation ~~January~~(“Parent”), 1and Cascade Merger Sub Inc., ~~2019:~~a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”). The board of directors of the Company has unanimously approved the Merger Agreement.

Name and Title	2018 Cash Bonus	2019 Annual Base Salary
Carlos Paya, M.D., Ph.D.President and Chief Executive Officer	$256,084	$620,628
Stephen BradyExecutive Vice President, Strategy and Finance	$141,316	$424,360
Jan ter Meulen, M.D.Chief Scientific Officer	$123,292	$412,309

Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, Purchaser will commence a tender offer (the “Offer”) no later than March 6, 2019, to acquire all of the outstanding shares of common stock of the Company, $0.001 par value per share (the “Shares”), at a purchase price of $5.85 per Share in cash (the “Offer Price”), without interest and subject to any required withholding of taxes.

~~Equity~~The ~~Awards~~obligation of Purchaser to purchase Shares tendered in the Offer is subject to the conditions set forth in the Merger Agreement, including that the number of Shares validly tendered in accordance with the terms of the Offer and not validly withdrawn, when considered together with all other Shares (if any) otherwise beneficially owned by Parent or any of its wholly owned subsidiaries (including Purchaser), would represent one more than 50% of the total number of Shares outstanding at the time of the expiration of the Offer (the “Minimum Condition”). The Purchaser’s obligation to consummate the Offer is not subject to a condition that any financing be received by Purchaser for the consummation of the transactions contemplated by the Merger Agreement.

~~The~~Following ~~Committee~~the ~~approved~~completion of the Offer and ~~granted~~subject ~~restricted~~to ~~stock~~the ~~units~~satisfaction or waiver of certain conditions set forth in the Merger Agreement, Purchaser will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the “~~RSUs~~Merger”). ~~and~~Purchaser ~~options~~will toeffect ~~purchase~~the ~~shares~~Merger after consummation of the ~~Company’s~~Offer ~~common~~pursuant ~~stock~~ to Section 251(h) of the ~~Executives~~Delaware asGeneral ~~annual~~Corporation ~~equity~~Law. ~~incentive~~At ~~awards~~the ~~granted~~effective time of the Merger (the “Effective Time”), the Shares not purchased pursuant to the Offer (other than Shares held by Parent, Purchaser, any other direct or indirect wholly owned subsidiary of Parent, the Company (or in the Company’s ~~2014~~treasury) ~~Omnibus~~or ~~Incentive~~by ~~Plan,~~stockholders ~~which~~of ~~grants~~the ~~are~~Company ~~set~~who ~~forth~~have perfected their statutory rights of appraisal under Delaware law) will each be converted into the right to receive an amount in cash equal to the ~~table~~Offer ~~below~~Price (the “Merger Consideration”), without interest and subject to any required withholding of taxes.

Name and Title	RSUs	Option Grant (shares)
Carlos Paya, M.D., Ph.D.President and Chief Executive Officer	63,000	293,000
Stephen BradyExecutive Vice President, Strategy and Finance	25,000	120,000
Jan ter Meulen, M.D.Chief Scientific Officer	25,000	120,000

Each of the Company’s stock options (the “Company Options”) that is outstanding as of immediately prior to the Effective Time shall accelerate and become fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Company, each Company Option that is then outstanding and unexercised as of immediately before the Effective Time shall be cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such fully vested Company Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per Share under such Company Option. No holder of a Company Option that has an exercise price per Share that is equal to or greater than the Merger Consideration shall be entitled to any payment with respect to such cancelled Company Option before or after the Effective Time.

Each ~~RSU~~of ~~granted~~the toCompany’s ~~each~~restricted ~~Executive~~stock ~~represents~~unit awards (the ~~right~~“Company toRSU Awards”) ~~receive~~that ~~one~~is ~~share~~outstanding as of immediately prior to the ~~Company’s~~Effective ~~common~~Time ~~stock~~shall accelerate and ~~has~~become afully ~~vesting~~vested ~~commencement~~effective ~~date~~immediately ofprior ~~January~~to, 4and contingent upon, ~~2019~~the Effective Time. ~~One-third~~In lieu of any issuance of Shares in settlement of such vested Company RSU Award, as of the ~~RSUs~~Effective ~~granted~~Time, toby ~~each~~virtue ~~Executive~~of ~~will~~the ~~vest~~Merger and without any further action on ~~each~~the ~~anniversary~~part of Parent, Purchaser, the ~~vesting~~Company, ~~commencement~~the ~~date~~holder ~~over~~of asuch ~~three-year~~Company ~~period~~RSU Award or any other Person, ~~subject~~each Company RSU Award that is outstanding shall be automatically cancelled and converted into the right to receive the ~~Executive’s~~Merger ~~continued~~Consideration ~~service~~in ~~with~~respect ~~the~~of each Share subject to such Company RSU Award, less applicable withholding obligations.

The ~~stock~~Merger ~~option~~Agreement ~~granted~~includes torepresentations, ~~each~~warranties ~~Executive~~and ~~has~~covenants ~~(i) a vesting commencement date~~ of ~~January~~the 3,parties ~~2019,~~customary ~~(ii)~~for ana ~~exercise~~transaction ~~price~~ of $1this nature.31 ~~per~~From ~~share,~~ the date ~~closing price~~ of the ~~Company’s~~Merger ~~common~~Agreement ~~stock~~until onthe ~~January~~earlier 3,of ~~2019~~the ~~and~~Effective ~~(iii)~~Time aand ~~term~~the termination of 10the ~~years~~Merger ~~from~~Agreement, the ~~grant~~Company ~~date.~~has ~~Twenty-five~~agreed ~~percent~~to ofoperate ~~the~~its ~~shares~~business ~~subject~~in to the ~~option~~ordinary ~~granted~~course toand ~~each~~has ~~Executive~~agreed ~~will~~to ~~vest~~certain onother ~~the~~operating ~~one-year~~covenants, ~~anniversary~~as ofset ~~the~~forth more ~~vesting~~fully ~~commencement~~in ~~date, and~~ the ~~remainder~~Merger ~~will~~Agreement. ~~vest~~The inCompany ~~equal~~has ~~monthly~~also ~~installments~~agreed ~~over~~not ~~the~~to ~~subsequent~~solicit ~~two-year~~or ~~period,~~initiate ~~subject~~discussions towith ~~the~~any ~~Executive’s~~third ~~continued~~party ~~service~~regarding ~~with~~acquisition ~~the Company~~proposals.

The Merger Agreement includes a remedy of specific performance for the Company, Parent and Purchaser. The Merger Agreement also includes customary termination provisions for both the Company and Parent and provides that, in connection with the termination of the Merger Agreement under specified circumstances, including termination by the Company to accept and enter into a definitive agreement with respect to an unsolicited superior offer, the Company will be required to pay a termination fee of an amount in cash equal to $10.5 million (the “Termination Fee”). Any such termination of the Merger Agreement by the Company is subject to certain conditions, including the Company’s compliance with certain procedures set forth in the Merger Agreement and a determination by the board of directors of the Company that the failure to take such action would be inconsistent with the board’s fiduciary duties to the Company’s stockholders under applicable law, payment of the Termination Fee by the Company and the execution of a definitive agreement by the Company with such third party.

Item 8.01

Other Events.

On February 21, 2019, the Company and Merck & Co., Inc. issued a joint press release announcing the execution of the Merger Agreement as described above. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

Additional Information

The foregoing description of the Merger Agreement is not complete and is qualified in its entirety by reference to the Merger Agreement, which is attached as Exhibit 2.1 to this report and incorporated herein by reference.

The Merger Agreement and the foregoing description of such agreement has been included to provide investors and stockholders with information regarding the terms of such agreement. The assertions embodied in the representations and warranties contained in the Merger Agreement are qualified by information in confidential disclosure schedules delivered by the Company to Parent and Purchaser in connection with the signing of the Merger Agreement. Moreover, certain representations and warranties in the Merger Agreement were made as of a specified date, may be subject to a contractual standard of materiality different from what might be viewed as material to stockholders, or may have been used for the purpose of allocating risk between the parties to the Merger Agreement. Accordingly, the representations and warranties in the Merger Agreement should not be relied on by any persons as characterizations of the actual state of facts and circumstances of the Company at the time they were made and should consider the information in the Merger Agreement in conjunction with the entirety of the factual disclosure about the Company in the Company’s public reports filed with the SEC. Information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.

Notice to Investors/Important Additional Information Filed with the U.S. Securities and Exchange Commission

This communication is not a recommendation, an offer to purchase or a solicitation of an offer to sell shares of Immune Design Corp. stock. Purchaser has not commenced the Offer for Shares described above. Upon commencement of the Offer, Parent and Purchaser will file with the U.S. Securities and Exchange Commission (the “SEC”) a tender offer statement on Schedule TO and related exhibits, including an offer to purchase, letter of transmittal, and other related documents. Following commencement of the tender offer, Immune Design Corp. will file with the SEC a solicitation/recommendation statement on Schedule 14D-9. Stockholders should read the offer to purchase and solicitation/recommendation statement and the tender offer statement on Schedule TO and related exhibits when such documents are filed and become available, as they will contain important information about the tender offer. Stockholders can obtain these documents when they are filed and become available free of charge from the SEC’s website at www.sec.gov or by contacting the investor relations department of Immune Design Corp. at the email address included below.

Contact:

Sylvia Wheeler & Katalin Janos

sylvia.wheeler@immunedesign.com

katalin.janos@immunedesign.com

In addition to the solicitation/recommendation statement, Immune Design Corp. files annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Immune Design Corp. at the SEC public reference room at 100 F Street, N.E., Washington, DC 201549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Immune Design Corp.’s filings with the SEC are also available to the public from commercial document-retrieval services and the SEC’s website at www.sec.gov.

Forward-Looking Statements

This communication may contain certain forward-looking statements regarding Immune Design Corp., including without limitation with respect to its business, the proposed tender offer and merger, the expected timetable for completing the transaction, the parties’ ability to satisfy the conditions to the Offer and the other conditions set forth in the Merger Agreement, the possibility of any termination of the Merger Agreement, and the strategic and other potential benefits of the transaction. Completion of the Offer and Merger are subject to conditions, including satisfaction of a minimum tender condition and required regulatory approvals, and there can be no assurance that those conditions can be satisfied or that the transactions described in this communication (the “Transactions”) will be completed or will be completed when expected. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, but are not limited to, the risk that not all conditions of the Offer or the Merger will be satisfied or waived; uncertainties regarding the two companies’ ability to successfully develop and market both new and existing products; uncertainties relating to the anticipated timing of filings and approvals relating to the Transactions; uncertainties as to the timing of the Offer and Merger; uncertainties as to how many of Immune Design Corp.’s stockholders will tender their stock in the Offer; the possibility that competing offers will be made; the failure to complete the Offer or the Merger in the timeframe expected by the parties or at all; the outcome of legal proceedings that may be instituted against Immune Design Corp. and/or others relating to the Transactions; Immune Design Corp.’s ability to maintain relationships with employees or vendors; domestic and global economic and business conditions; and other risk factors described in Immune Design Corp.’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. The reader is cautioned not to unduly rely on these forward-looking statements. Any forward-looking statements in this communication are based on information known to Immune Design Corp. on the date of this announcement. Immune Design Corp. does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.


Number		Description

2.1*		Agreement and Plan of Merger, dated as of February 20, 2019, by and among Immune Design Corp., Merck Sharp & Dohme Corp. and Cascade Merger Sub Inc.

99.1		Joint Press Release of Immune Design Corp. and Merck & Co., Inc. dated February 21, 2019.

*	Schedules omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNE DESIGN CORP. By: /s/ Carlos Paya, M.D., Ph.D. Carlos Paya, M.D., Ph.D. President and Chief Executive Officer


	IMMUNE DESIGN CORP.
Dated: February 21, 2019

	By:	/s/ Carlos Paya, M.D., Ph.D
		Carlos Paya, M.D., Ph.D.
		President and Chief Executive Officer

Dated: January 8, 2019

Filing Compare · IMMUNE DESIGN CORP.